Safety and Efficacy of Dexamethasone Ophthalmic Insert (Dextenza®) in the Management of Clinically Significant Dry Eye

PHASE4

Phase

TERMINATED

Status

Enrollment

OTHER

Sponsor class

Stopped The study was terminated prematurely due to administrative reasons; loss of several research personnel. Because of strict eligibility criteria, the investigators anticipated delays in completing enrollment and therefore decided to terminate early.

Conditions

Dry Eye

Interventions

DRUG: Sustained Release Dexamethasone, 0.4 mg
OTHER: E-Caprolactone-L-Lactide copolymer (PCL) punctal plug

Sponsor

Johns Hopkins University